Immune checkpoint inhibitors
- PDF / 169,621 Bytes
- 1 Pages / 595.245 x 841.846 pts (A4) Page_size
- 53 Downloads / 214 Views
1 S
Various toxicities: 6 case reports In a retrospective study of 19 dialysis patients who received immune checkpoint inhibitors between 2013 and 2019, six patients [ages and sexes not stated] were described, who developed hypothyroidism, hearing loss, myositis, myocarditis or pneumonitis during treatment with avelumab, ipilimumab, nivolumab or pembrolizumab for Merkel cell carcinoma, melanoma, lung cancer, head and neck cancer or genitourinary cancer. The patients were on dialysis. The patients had a history of Merkel cell carcinoma, melanoma, lung cancer, head and neck cancer or genitourinary cancer. The patients had been receiving avelumab (1 patient), nivolumab (1 patient), ipilimumab and nivolumab (1 patient) and pembrolizumab (3 patients) [dosages and routes not stated]. Subsequently, the patients developed immune-related adverse events comprising hypothyroidism (3 patients), hearing loss and myositis (1 patient), myocarditis (1 patient) and pneumonitis (1 patient) [durations of treatments to reactions onsets not stated]. The patient with myocarditis had a persistently low left ventricular ejection fraction and died 5 months later of an unclear cause. Three out of the six patients, who had developed hypothyroidism, were treated with levothyroxine sodium [levothyroxine] [outcomes not stated]. Strohbehn IA, et al. Safety and Efficacy of Immune Checkpoint Inhibitors in Patients on Dialysis: A Retrospective Case Series. American Journal of Kidney Diseases 76: 803502304 299-302, No. 2, Aug 2020. Available from: URL: http://doi.org/10.1053/j.ajkd.2020.02.451
0114-9954/20/1822-0001/$14.95 Adis © 2020 Springer Nature Switzerland AG. All rights reserved
Reactions 19 Sep 2020 No. 1822
Data Loading...
